Terumo (OTCMKTS:TRUMY) Stock Rating Upgraded by Nomura

Terumo (OTCMKTS:TRUMY) was upgraded by Nomura from a “hold” rating to a “strong-buy” rating in a research note issued on Thursday,Zacks.com reports.

Separately, Zacks Research raised shares of Terumo to a “hold” rating in a research report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Terumo currently has an average rating of “Buy”.

Terumo Stock Performance

OTCMKTS:TRUMY opened at $14.53 on Thursday. The company’s 50-day moving average is $14.01 and its two-hundred day moving average is $13.54. Terumo has a 1-year low of $12.08 and a 1-year high of $19.60. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.59 and a quick ratio of 0.97. The firm has a market capitalization of $21.43 billion, a price-to-earnings ratio of 23.82 and a beta of 0.68.

Terumo (OTCMKTS:TRUMY) last announced its quarterly earnings results on Friday, May 15th. The company reported $0.11 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.11. Terumo had a net margin of 12.09% and a return on equity of 9.17%. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.84 billion. Analysts forecast that Terumo will post 0.7 EPS for the current year.

Terumo Company Profile

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.